ACE-031
Activin Receptor Type IIB-Fc
A fusion protein that inhibits myostatin and related proteins by binding to activin receptors. Developed for muscular dystrophy treatment.
Typical Cost
Not commercially available
Status
Research
Peptide Profile
ACE-031
Mechanism of Action
Binds to activin type IIB receptors, blocking myostatin and related growth factors from exerting their muscle-limiting effects. Results in rapid and substantial muscle growth beyond normal genetic limits.
Common Dosages
subcutaneous
1-3mg/kg
Weekly · Clinical trial dosing
Benefits
Rapid muscle growth
Dramatic strength increases
Muscle disease treatment potential
Side Effects
Nosebleeds
Skin telangiectasia
Gum bleeding
Safety concerns halted development
Key Research
ACE-031 in muscular dystrophy
Demonstrated significant lean mass increases but trials halted due to safety concerns
Regulatory Status
Clinical trials halted due to safety concerns (nosebleeds, skin changes). Not approved. Research chemical status.
Contraindications
- ⚠All users due to safety profile
- ⚠Bleeding disorders
- ⚠Pregnancy/breastfeeding
Safety concerns make this inappropriate. SeraVia Muscle+ Protect provides safe, proven muscle support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.